MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
C4 Therapeutics, Inc. (NASDAQ: CCCC)*
Organization & Developments: C4 Therapeutics
Parents
C4 Therapeutics, Inc. (NASDAQ: CCCC)*
Children
*C4 was founded to develop its TORPEDO platform which synthesizes small molecule protein degraders delivered via oral administration for the treatment of blood and other cancers.
2020: C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach
2023: C4 Therapeutics discontinues cancer program, waits for Betta payment
2023: C4 Therapeutics: Merck News Does Not Make It A Buy Yet, But Upgrading To Hold_seekingalpha.com
2024: C4 Therapeutics Launches Phase 1 Trial in China: $357M Cancer Drug Partnership Advances
2024: C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout_ seekingalpha.com
2024: C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
2025: C4 Therapeutics: An Entry Point If There's Ever Going To Be One
2025: C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here
Jumps
Finance & Acquisitions: C4 Therapeutics
Key People: C4 Therapeutics